Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewGoSlo SR 5-69
Description: BK channel activator
Chemical Name: Sodium 1-Amino-9,10-dioxo-4-((5,6,7,8-tetrahydronaphthalen-2-yl)amino)-9,10-dihydroanthracene-2-sulfonate
Purity: ≥98% (HPLC)
Biological Activity
BK channel activator (EC50 = 251 nM). Shifts the voltage required for half maximal negatively (DV1/2 = -104 mV).
Technical Data
| M. Wt | 470.47 |
| Formula | C24H19N2NaO5S |
| Storage | Store at RT |
| Purity | ≥98% (HPLC) |
| CAS Number | 1363419-31-1 |
| PubChem ID | 56944133 |
| InChI Key | JOJJZTFRBZWSBX-UHFFFAOYSA-M |
| Smiles | NC1=C2C(C3=CC=CC=C3C(C2=C(C=C1S(=O)([O-])=O)NC4=CC=C5CCCCC5=C4)=O)=O.[Na+] |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 47.05 | 100 |
Preparing Stock Solutions
The following data is based on the product molecular weight 470.47. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.13 mL | 10.63 mL | 21.26 mL |
| 5 mM | 0.43 mL | 2.13 mL | 4.25 mL |
| 10 mM | 0.21 mL | 1.06 mL | 2.13 mL |
| 50 mM | 0.04 mL | 0.21 mL | 0.43 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets
References
References are publications that support the biological activity of the product.
Roy et al (2014) Development of GoSlo-SR-5-69, a potent activator of large conductance Ca2+-activated K+ (BK) channels. Eur.J.Med.Chem. 75 426 PMID: 24561672
Schewe et al (2019) A pharmacological master key mechanism that unlocks the selectivity filter gate in K+ channels. Science 363 875 PMID: 30792303
If you know of a relevant reference for GoSlo SR 5-69, please let us know.
View Related Products by Target
View Related Products by Product Action
View all Calcium-Activated Potassium (KCa) Channel Activators
Keywords: GoSlo SR 5-69, GoSlo SR 5-69 supplier, GoSloSo5-69, SR569, BK, channels, activators, activates, Ca2+-Activated, Potassium, Channels, 5814, Tocris Bioscience
Citations for GoSlo SR 5-69
Citations are publications that use Tocris products.
Currently there are no citations for GoSlo SR 5-69. Do you know of a great paper that uses GoSlo SR 5-69 from Tocris? Please let us know.
Reviews for GoSlo SR 5-69
There are currently no reviews for this product. Be the first to review GoSlo SR 5-69 and earn rewards!
Have you used GoSlo SR 5-69?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Ion Channel Product Listing
A collection of around 500 products for ion channel research, the listing includes research tools for the study of:
- Ligand-gated ion channels
- Voltage-gated ion channels
- Other Ion Channels
Epilepsy Poster
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.